<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01900041</url>
  </required_header>
  <id_info>
    <org_study_id>MRU20040_4002_1</org_study_id>
    <nct_id>NCT01900041</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss</brief_title>
  <official_title>Multicenter, Randomised, Open Label, Comparative Clinical Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss (Including AGA Ludwig's Type 1-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LLC Merz Pharma, Russia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pantovigar - a high effective product designed primarily for the treatment of diffuse hair
      loss in women as well as for the treatment of damaged hair, in the combined therapy can be
      successfully applied in other types of alopecia.

      The purpose of this study is to evaluate efficacy and tolerability of combination therapy
      Pantovigar plus 2% minoxidil vs 2% minoxidil. To collect tolerability data for combined
      treatment Pantovigar plus 2% Minoxidil course therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of responders to the treatment</measure>
    <time_frame>Week 16-20 post baseline</time_frame>
    <description>Assessed by the Investigator using the results photo trichogram (TrichoScience). Responders are defined to fulfill at least one of the following criteria:
Reduction in the amount of telogen hair to 15% and below
Increasing hair growth density
Thickening of average hair diameter
Reduction in the amount of vellus hair in comparison with initial indicators</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Female Pattern Hair Loss</condition>
  <condition>Androgenetic Alopecia (AGA)</condition>
  <condition>Ludwig Type 1</condition>
  <condition>Ludwig Type 2</condition>
  <arm_group>
    <arm_group_label>Pantovigar + Minoxidil 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minoxidil 2% is given as background therapy in both arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minoxidil 2% only</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Minoxidil 2% is given as background therapy in both arms</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantovigar</intervention_name>
    <description>1 capsule of Pantovigar for oral intake, given three times a day. Duration of treatment: 6 months.</description>
    <arm_group_label>Pantovigar + Minoxidil 2%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minoxidil 2% only</intervention_name>
    <description>1 ML of Minoxidil 2% solution twice a day applied to the scalp. Duration of treatment: 6 months.</description>
    <arm_group_label>Pantovigar + Minoxidil 2%</arm_group_label>
    <arm_group_label>Minoxidil 2% only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patient complaint of hair loss and/or hair density reduction for more than 3
             months.

          -  More than 15 % of telogen frontoparietal hair as shown in the phototrichogram.

        Exclusion Criteria:

          -  Symptomatic diffuse alopecia (screening for iron and thyroid function, thyroid
             stimulating hormon, triiodothyrine, ferritin , total iron-binding capacity)

          -  Active or history of systemic autoimmune disease, e.g. lupus erythematodes etc.

          -  Hyperandrogenic alopecia (polycystic ovary syndrome, adrenogenital syndrome, tumors
             with androgenic activity) (testosterone, prolactin hormone, androstenedione,
             dehydroepiandrosterone)

          -  Initiation or termination of hormone therapy within 6 months prior to entering study

          -  Hormone therapy with androgenic action, e.g. norethisterone etc.

          -  Pregnancy or lactation within 6 months prior to entering study

          -  Alopecia areata

          -  Scarring alopecia

          -  Treatment with hair promoting agent within 3 months prior to entering study

          -  Known hair loss after drug intake

          -  Concomitant use of the drugs causing a hair loss (e.g. aromatase inhibitors,
             thyreostatics, cytostatics, etc,)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>LLC Merz Pharma, Russia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State Scientific Center of Dermatology and Cosmetology</name>
      <address>
        <city>Moscow</city>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Scientific Clinical Center of Dermatology and Cosmetology</name>
      <address>
        <city>Moscow</city>
        <zip>119071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2013</study_first_submitted>
  <study_first_submitted_qc>July 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2013</study_first_posted>
  <last_update_submitted>December 11, 2013</last_update_submitted>
  <last_update_submitted_qc>December 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minoxidil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

